Transgene Biotek [TRABI] vs Dishman Carbogen [DCAL] Detailed Stock Comparison
Transgene Biotek
BSE
Loading...
Dishman Carbogen
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Transgene Biotek wins in 4 metrics, Dishman Carbogen wins in 14 metrics, with 0 ties. Dishman Carbogen appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Transgene Biotek | Dishman Carbogen | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -48.67 | 40.24 | Transgene Biotek |
| Price-to-Book Ratio | 3.04 | 0.72 | Dishman Carbogen |
| Debt-to-Equity Ratio | 144.77 | 40.97 | Dishman Carbogen |
| PEG Ratio | 0.16 | -0.31 | Dishman Carbogen |
| EV/EBITDA | -47.44 | 10.14 | Transgene Biotek |
| Profit Margin (TTM) | 100.00% | 3.60% | Transgene Biotek |
| Operating Margin (TTM) | -380.20% | 8.38% | Dishman Carbogen |
| EBITDA Margin (TTM) | N/A | 8.38% | N/A |
| Return on Equity | -6.74% | 0.06% | Dishman Carbogen |
| Return on Assets (TTM) | -0.47% | 0.03% | Dishman Carbogen |
| Free Cash Flow (TTM) | $-5.04M | $1.58B | Dishman Carbogen |
| 1-Year Return | -43.99% | 45.41% | Dishman Carbogen |
| Price-to-Sales Ratio (TTM) | 116.70 | 1.45 | Dishman Carbogen |
| Enterprise Value | $415.59M | $60.00B | Dishman Carbogen |
| EV/Revenue Ratio | 159.23 | 2.07 | Dishman Carbogen |
| Gross Profit Margin (TTM) | 100.00% | 86.15% | Transgene Biotek |
| Revenue per Share (TTM) | $0 | $188 | Dishman Carbogen |
| Earnings per Share (Diluted) | $-0.18 | $6.65 | Dishman Carbogen |
| Beta (Stock Volatility) | 0.80 | 0.19 | Dishman Carbogen |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Transgene Biotek vs Dishman Carbogen Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Transgene Biotek | -9.82% | 14.66% | -1.13% | 1.86% | 14.06% | -28.78% |
| Dishman Carbogen | 2.98% | 2.36% | 5.70% | 6.73% | 31.21% | -2.51% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Transgene Biotek | -43.99% | 36.45% | -0.45% | 48.98% | -91.63% | -95.45% |
| Dishman Carbogen | 45.41% | 185.57% | 82.33% | 84.06% | 194.71% | 290.06% |
News Based Sentiment: Transgene Biotek vs Dishman Carbogen
Transgene Biotek
News based Sentiment: NEGATIVE
The initiation of insolvency proceedings is a game-changing event for Transgene Biotek Ltd., significantly increasing the risk for investors. Coupled with consistent losses and a declining market cap, the company faces a very uncertain future, making this a critical month for its investment story.
Dishman Carbogen
News based Sentiment: POSITIVE
Dishman Carbogen Amcis is demonstrating a clear turnaround, with significant revenue growth and a return to profitability. While challenges remain in translating revenue into bottom-line profits and past earnings declines, the company's strategic investments in ESG and leadership stability suggest a positive trajectory for investors.
Performance & Financial Health Analysis: Transgene Biotek vs Dishman Carbogen
| Metric | TRABI | DCAL |
|---|---|---|
| Market Information | ||
| Market Cap | ₹335.38M | ₹41.96B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 95,533 | 191,348 |
| 90 Day Avg. Volume | 53,167 | 144,601 |
| Last Close | ₹3.95 | ₹286.45 |
| 52 Week Range | ₹3.22 - ₹7.71 | ₹161.21 - ₹307.98 |
| % from 52W High | -48.77% | -6.99% |
| All-Time High | ₹322.50 (Jan 23, 2006) | ₹396.40 (Jan 22, 2018) |
| % from All-Time High | -98.78% | -27.74% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.00% | 0.35% |
| Quarterly Earnings Growth | 0.01% | 0.35% |
| Financial Health | ||
| Profit Margin (TTM) | 1.00% | 0.04% |
| Operating Margin (TTM) | -3.80% | 0.08% |
| Return on Equity (TTM) | -0.07% | 0.00% |
| Debt to Equity (MRQ) | 144.77 | 40.97 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹1.32 | ₹372.17 |
| Cash per Share (MRQ) | ₹0.04 | ₹33.89 |
| Operating Cash Flow (TTM) | ₹1.93M | ₹-187,700,000 |
| Levered Free Cash Flow (TTM) | ₹-6,761,000 | ₹32.40M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Transgene Biotek vs Dishman Carbogen
| Metric | TRABI | DCAL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -48.67 | 40.24 |
| Forward P/E | N/A | 21.41 |
| PEG Ratio | 0.16 | -0.31 |
| Price to Sales (TTM) | 116.70 | 1.45 |
| Price to Book (MRQ) | 3.04 | 0.72 |
| Market Capitalization | ||
| Market Capitalization | ₹335.38M | ₹41.96B |
| Enterprise Value | ₹415.59M | ₹60.00B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 159.23 | 2.07 |
| Enterprise to EBITDA | -47.44 | 10.14 |
| Risk & Other Metrics | ||
| Beta | 0.80 | 0.19 |
| Book Value per Share (MRQ) | ₹1.32 | ₹372.17 |
Financial Statements Comparison: Transgene Biotek vs Dishman Carbogen
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TRABI | DCAL |
|---|---|---|
| Revenue/Sales | ₹765,000 | ₹7.16B |
| Cost of Goods Sold | ₹0 | ₹1.46B |
| Gross Profit | ₹765,000 | ₹5.70B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-5.66M | ₹736.00M |
| EBITDA | ₹-4.98M | ₹1.61B |
| Pre-Tax Income | ₹-7.13M | ₹277.00M |
| Income Tax | ₹0 | ₹-153.90M |
| Net Income (Profit) | ₹-7.13M | ₹430.90M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TRABI | DCAL |
|---|---|---|
| Cash & Equivalents | ₹2.84M | ₹3.41B |
| Total Current Assets | ₹12.64M | ₹22.00B |
| Total Current Liabilities | ₹127.38M | ₹19.25B |
| Long-Term Debt | ₹61.03M | ₹13.90B |
| Total Shareholders Equity | ₹100.30M | ₹58.32B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹32.85M | ₹29.19B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TRABI | DCAL |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TRABI | DCAL |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 95,533 | 191,348 |
| Average Daily Volume (90 Day) | 53,167 | 144,601 |
| Shares Outstanding | 75.77M | 156.78M |
| Float Shares | 48.28M | 55.23M |
| % Held by Insiders | 0.22% | 0.71% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Transgene Biotek vs Dishman Carbogen
| Metric | TRABI | DCAL |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |